{"id":974771,"date":"2026-06-23T09:55:43","date_gmt":"2026-06-23T13:55:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-expands-availability-of-precise-mrd-for-colorectal-renal-and-breast-cancers-supported-by-new-publication\/"},"modified":"2026-06-23T09:55:43","modified_gmt":"2026-06-23T13:55:43","slug":"myriad-genetics-expands-availability-of-precise-mrd-for-colorectal-renal-and-breast-cancers-supported-by-new-publication","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-expands-availability-of-precise-mrd-for-colorectal-renal-and-breast-cancers-supported-by-new-publication\/","title":{"rendered":"Myriad Genetics Expands Availability of Precise MRD\u2122 for Colorectal, Renal and Breast Cancers, Supported by New Publication"},"content":{"rendered":"

\nPublication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD
\n<\/h2>\n
\n

SALT LAKE CITY, June 23, 2026 (GLOBE NEWSWIRE) — Myriad Genetics, Inc.<\/a>, (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces expanded availability of Precise MRD\u2122, broadening availability to patients undergoing treatment and surveillance for breast, colorectal and renal cancers. More than 6 million individuals are living with these cancers in the U.S., representing a significant expansion in access to Myriad\u2019s ultrasensitive Precise MRD test1<\/sup>.<\/p>\n

Precise MRD is a next-generation, ultrasensitive, whole-genome sequencing-based assay that generates a personalized panel for each patient by tracking up to 1,000 variants. The test provides clinicians with a dynamic and quantitative molecular view of their patient\u2019s disease status across the cancer care continuum, from neoadjuvant therapy through post-surgical assessment and long-term surveillance. Its ultrasensitive design enables robust detection of circulating tumor DNA (ctDNA) even in low-shedding tumors, delivering consistent performance across a range of disease settings2<\/sup>.<\/p>\n

\u201cExpanding Precise MRD into breast, colorectal and renal cancers marks a significant step forward in our broader precision oncology strategy,\u201d said Brian Donnelly, Chief Commercial Officer, Myriad Genetics. \u201cIn a single, easy-to-read report, Precise MRD delivers ultrasensitive ctDNA detection and longitudinal insights, along with the clinical interpretation support clinicians need to help guide treatment and surveillance decisions. As we continue to expand across tumor types and build clinical evidence, we believe Precise MRD will play an increasingly central role in managing cancer care.\u201d<\/p>\n

\n MONITOR-Breast publication adds to growing evidence for Precise MRD<\/strong>
\n
Myriad Genetics also announces the publication of results from the prospective, multi-center MONITOR-Breast study in Future Oncology<\/em><\/a>, further supporting the clinical validity of Precise MRD in breast cancer. The study demonstrates that ultrasensitive ctDNA monitoring during neoadjuvant therapy provided real-time insight into treatment response and helped identify patients at increased risk for residual disease.<\/p>\n

“MONITOR-Breast highlights the strength of a whole-genome, tumor-informed approach to MRD detection,” said Dale Muzzey, Chief Scientific Officer, Myriad Genetics. “Precise MRD enables ultrasensitive ctDNA detection and longitudinal disease monitoring that captures dynamic treatment response. The ability to identify additional at-risk patients through frequent sampling, beyond a single timepoint assessment, demonstrates the importance of molecular monitoring in improving risk stratification and guiding clinical decision-making.”<\/p>\n

The study evaluated 154 patients with Stage I\u2013III breast cancer across all molecular subtypes, analyzing 949 plasma samples collected longitudinally throughout treatment using Precise MRD to assess ctDNA status. Key findings include:<\/p>\n